TTX 3360
Alternative Names: TTX-3360Latest Information Update: 28 Aug 2024
At a glance
- Originator Triplet Therapeutics
- Class Antisense oligonucleotides
- Mechanism of Action DNA damage modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Huntington's-disease in USA (Intracerebral, Injection)
- 27 Apr 2021 Pharmacodynamics data from a preclinical study in Huntington's disease released by Triplet Therapeutics
- 28 Jul 2020 TTX 3360 is available for licensing as of 28 Jul 2020 https://www.triplettx.com/contact.html (Triplet Therapeutics website, July 2020)